Access in all areas? A round-up of developments in market access and health technology assessment: part 10
In this update, we examine the US' Food and Drug Administration (FDA) Commissioner's National Priority Voucher pilot program; The Netherlands' Zorginstituut Nederland (ZIN) implementation framework for the EU HTA Regulation; and Italy's Agenzia Italiana del Farmaco (AIFA) refined criteria for assessing therapeutic innovativeness.
Authors
- Sreeram V Ramagopalan (ORCID: https://orcid.org/0000-0002-4766-5160)
- Annie Jullien Pannelay
Institutions
- King's College London (GB)
- BirdLife International (KE)
Publication Details
- Journal
- Journal of Comparative Effectiveness Research
- Published
- 2025-09-16
- DOI
- https://doi.org/10.57264/cer-2025-0138
- Citations
- 1
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 3.13
Funders
- Zorginstituut Nederland
- Agenzia Italiana del Farmaco, Ministero della Salute